ClinicalTrials.gg
WithdrawnNCT05444153PIONEER STARTUpdated Nov 14, 2022

Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity

A Phase 3 interventional study of Semaglutide and Empagliflozin in Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Withdrawn. Per ClinicalTrials.gov, last updated 2022-11-14.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 163 studies testing semaglutide in Diabetes Mellitus, Type 2 — 35 open to participants now, 45 under way, 9 of them phase 3. Semaglutide · Diabetes Mellitus, Type 2.

Enrollment
161st of 163
0 · median 104
Started
2022
with 17 others
Phase 3
57 of 163
7 open now
Registered
101st of 163
by date
Lead sponsor
89 of 163
Novo Nordisk A/S

Among the 163 studies testing semaglutide in Diabetes Mellitus, Type 2, this one is the 161st largest by enrollment, is one of 18 that started in 2022, is one of 57 in phase 3, and was the 101st registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

35 of the 163 studies testing semaglutide in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

30 more — sign in →

By country, each count listing its studies:

All 35 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 163 studies testing semaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study compares the medicines semaglutide and empagliflozin in people with newly diagnosed type 2 diabetes and obesity. The study will look mainly at how well the blood sugar and body weight are controlled when participants are taking the study medicine. Participants will either get semaglutide tablets or empagliflozin tablets. Which treatment participants get is decided by chance. Participants will get one tablet per day for 2 years. The study will last for about 2 years and 8 weeks.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, age 18- less than (\<) 50 years at the time of signing .
  • Diagnosed with type 2 diabetes mellitus less than or equal to (\<=) 365 days from the day of screening.
  • (HbA1c) of 7.0-9.5 percentage (%) (53-80 millimoles per milliliter [mmol/mol]) (both inclusive).
  • (BMI) greater than or equal to (>=) 30.0 kilograms per meter square (kg/m\^2).
  • Treatment naïve to any antidiabetic drug(s). However, for a subset of participants (≤25%) any metformin dose or formulations administered is allowed.

Exclusion criteria

Exclusion Criteria:

  • Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria since diagnosed with type 2 diabetes mellitus. Prior insulin treatment for gestational diabetes is allowed.
  • Renal impairment measured as estimated (eGFR) value of less than (\<) 60 milliliter per minute per 1.73 meter square (1.7mL/min/1.73 m\^2) at screening.
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days prior to day of screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
  • C-peptide less than (\<)1.5 nanograms per milliliter (ng/mL) at screening.
  • Positive insulinoma associated-protein 2 (IA-2) antibodies or anti-glutamic acid decarboxylase (anti-GAD) antibodies.
  • History of major surgical procedures involving the stomach or small intestine potentially affecting absorption of drugs and/or nutrients.
  • Presence of gastrointestinal disorders potentially affecting absorption of drugs and/or nutrients, as judged by the investigator.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Oral semaglutide

    Participants will receive once daily oral semaglutide tablet for 104 weeks in a dose escalation fashion of 3milligrams (mg), 7mg, 14 mg and 25 mg once every four weeks during the first 16 weeks and a maintenance dose of 55 mg for the rest 88 weeks.

    Drug: Semaglutide

  • Active comparator
    Empagliflozin

    Participants will receive once daily empagliflozin tablet for up to 104 weeks, starting with a dose of 10 mg for the first 8 weeks and the maintenance dose of 25 mg for the rest 96 weeks.

    Drug: Empagliflozin

Interventions

  • Participants will receive 1 tablet of oral semaglutide once daily.

  • Participants will receive 1 tablet of empagliflozin once daily.

06

What researchers measure

Primary outcomes

  1. Participants acheiving glycated haemoglobin (HbA1c) less than (<) 7 percentage (%) (Yes/No)

    Measured as count of participants.

    Time frame: At week 104

  2. Participants acheiving body weight reduction greater than or equal to (>=) 5% (Yes/No)

    Measured as count of participants.

    Time frame: At week 104

Secondary outcomes

  1. Change in HbA1c

    Measured as percentage (%)-point.

    Time frame: From randomisation (week 0) to week 104

  2. Change in fasting plasma glucose (FPG)

    Measured in millimoles per liter (mmol/l).

    Time frame: From randomisation (week 0) to week 104

  3. Change in self-measured plasma glucose (SPMG) 7-point mean profile

    Measured in millimoles per liter(mmol/l).

    Time frame: From randomisation (week 0) to week 104

  4. Change in self-measured plasma glucose (SPMG) mean post prandial increments

    Measured in millimoles per liter(mmol/l).

    Time frame: From randomisation (week 0) to week 104

  5. Time to additional anti-diabetic medication

    Measured in days.

    Time frame: From randomisation (week 0) to week 104

  6. Change in body weight

    Measured in kilograms (kg).

    Time frame: From randomisation (week 0) to week 104

  7. Relative change in body weight

    Measured as percentage (%).

    Time frame: From randomisation (week 0) to week 104

  8. Change in waist circumference

    Measured in centimeters (cm).

    Time frame: From randomisation (week 0) to week 104

  9. Participants achieving glycated haemoglobin (HbA1c) less than or equal to (<=) 6.5% (Yes/No)

    Measured as count of participants.

    Time frame: From randomisation (week 0) to week 104

  10. Participants achieving glycated haemoglobin (HbA1c) reduction greater than or equal to (>=) 0.7%-point (Yes/No)

    Measured as count of participants.

    Time frame: From randomisation (week 0) to week 104

  11. Participants achieving body weight reduction greater than or equal to (>=) 5 percentage (%)

    Measured as count of participants.

    Time frame: From randomisation (week 0) to week 104

  12. Change in systolic blood pressure

    Measured in millimiters of mercury (mmHg).

    Time frame: From randomisation (week 0) to week 104

  13. Change in total cholesterol

    Measured as ratio to baseline.

    Time frame: From randomisation (week 0) to week 104

  14. Change in high density lipoprotein (HDL)

    Measured as ratio to baseline.

    Time frame: From randomisation (week 0) to week 104

  15. Change in low density lipoprotein (LDL)

    Measured as ratio to baseline.

    Time frame: From randomisation (week 0) to week 104

  16. Change in very low density lipoprotein (VLDL)

    Measured as ratio to baseline.

    Time frame: From randomisation (week 0) to week 104

  17. Change in Triglycerides

    Measured as ratio to baseline.

    Time frame: From randomisation (week 0) to week 104

  18. Change in free fatty acids

    Measured as ratio to baseline.

    Time frame: From randomisation (week 0) to week 104

  19. Number of treatment emergent adverse events

    Measured as count of events.

    Time frame: From randomisation (week 0) to week 109

  20. Change in Control of Eating Questionnaire (CoEQ) score - Craving Control domain

    Measured as score on a scale. Scales range from 0 (minimum) to 10 (maximum).

    Time frame: From randomisation (week 0) to week 104

  21. Change in Control of Eating Questionnaire (CoEQ) score - Craving for Savory domaina

    Measured as score on a scale. Scales range from 0 (minimum) to 10(maximum).

    Time frame: From randomisation (week 0) to week 104

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2022; primary completion for Oct 2024, 23 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2022
First posted
Jul 5, 2022
StartEst.
Oct 6, 2022
Primary completionEst.
Oct 2, 2024
CompletionEst.
Aug 29, 2025
Last update
Nov 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05444153
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jul 5, 2022
Start date
Oct 6, 2022 (estimated)
Primary completion
Oct 2, 2024 (estimated)
Completion
Aug 29, 2025 (estimated)
Last update
Nov 14, 2022

Study contacts

Clinical Transparency dept. 2834
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion